Drug Patents owned by Neurelis Inc
1. List of Valtoco drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10265402 | NEURELIS INC | Absorption enhancers for drug administration |
May, 2025
(1 year, 11 months from now) | |
| US9642913 | NEURELIS INC | Pharmaceutical composition including alkyl glycoside and an anti-seizure agent |
May, 2025
(1 year, 11 months from now) | |
| US8927497 | NEURELIS INC | Absorption enhancers for intranasal administration |
Jul, 2025
(2 years from now) | |
| US8895546 | NEURELIS INC | Administration of benzodiazepine compositions |
Mar, 2029
(5 years from now) | |
| US11241414 | NEURELIS INC | Administration of benzodiazepine compositions |
Mar, 2029
(5 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Product (NP) | Jan 10, 2023 |
| Orphan Drug Exclusivity (ODE) | Jan 10, 2027 |
Drugs and Companies using DIAZEPAM ingredient
Market Authorisation Date: 10 January, 2020
Treatment: Nasal administration of diazepam for treatment of intermittent, stereotypic episodes of frequent seizure activity in patients 6 years of age and older
Dosage: SPRAY;NASAL
VALTOCO family patents
60
United States
10
European Union
9
Japan
5
Spain
5
China
5
Australia
4
Denmark
4
Canada
3
Korea, Republic of
3
United Kingdom
2
Hong Kong
2
Brazil
1
Poland
1
Germany
1
Russia
1
Morocco
1
Singapore
1
EA
1
New Zealand
1
Israel
1
Portugal
1
Mexico
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic